Reagents News and Research

RSS

Ventana, CST enter license agreement for personalized cancer diagnostics

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.

From Cell Signaling Technology 16 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Geospiza, NuGEN partner to develop seamless next-generation sequencing workflow

Geospiza, Inc., the market leading developer of genetic analysis software, and NuGEN Technologies, Inc., the leader in sample preparation solutions for clinical samples, today announced a co-marketing agreement to develop a seamless next-generation sequencing workflow to accelerate discoveries for large disease research studies.

9 Mar 2011

Roche, OraSure receive FDA 510(k) clearance for Oral Fluid Drug Testing System

OraSure Technologies, Inc. and Roche announced today that the U.S. Food and Drug Administration has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept Oral Fluid Drug Testing System.

3 Mar 2011

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA.

2 Mar 2011

Renishaw launches first RUO multiplex assay system

Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering and surface enhanced resonance Raman scattering, for research and molecular diagnostics applications, today announced the launch of its first research use only multiplex assay system which allows precious research samples to be 'screened' for 10 or more 'targets', from a single sample.

1 Mar 2011

Agilent Technologies acquires Lab901

Agilent Technologies Inc. today announced it has acquired Lab901, a leading electrophoresis equipment and consumables company based in Edinburgh, U.K. The company's automated electrophoresis products are used for DNA, RNA and protein analysis. Financial details of the acquisition were not disclosed.

28 Feb 2011

NanoString launches fixed-panel assay product for human molecular karyotyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the first fixed-panel assay product to be developed on its Copy Number Variation detection platform - the nCounter Human Karyotype Panel.

From NanoString Technologies 22 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

China Medical Technologies third quarter revenues increase 30.0% to RMB223.9 million ($33.9M)

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the third fiscal quarter ended December 31, 2010 ("3Q FY2010") today.

19 Feb 2011

U.S. Patent Office issues Notice of Allowance to Biomoda's CyPath assay for cancer detection

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent application on a quantitative method for scoring cells labeled with the CyPath assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

17 Feb 2011

WaferGen offers SNP Genotyping screening with new SmartChip PCR System

WaferGen Biosystems, Inc. a leading developer of state-of-the-art genomic analysis systems, today announced that it is offering an early access program for high-throughput Single Nucleotide Polymorphism Genotyping through its new SmartChip Real-Time PCR System.

16 Feb 2011

New review of anthrax case discussed by review committee vice chair, Stanford bioterrorism expert

In 2001, a mystery perpetrator mailed a series of anthrax-laced letters to several locations, killing five people. In 2008, shortly after emerging as the prime suspect in an exhaustive investigation by the FBI, an Army microbiologist, Bruce Ivins, PhD, committed suicide. This morning, a National Academy of Sciences committee, charged in September 2008 with reviewing the scientific approaches used by the FBI in that investigation, released its report.

15 Feb 2011

New England Biolabs adds OneTaq and OneTaq Hot Start DNA Polymerases to line of PCR reagents

New England Biolabs has expanded its line of PCR reagents to include OneTaq™ and OneTaq Hot Start DNA Polymerases. Optimized blends of Taq and Deep Vent® DNA Polymerases, these new products offer robust amplification across a wide range of templates, including routine, AT-rich and GC-rich amplicons.

From New England Biolabs 15 Feb 2011

GE Capital supports eBioscience with $55 million in senior secured credit facilities

GE Capital, Healthcare Financial Services announced today that it is agent and a lender for $55 million in senior secured credit facilities for eBioscience, Inc. The credit facilities will be used to finance the company's repurchase of certain shares from early investors, refinance existing debt, and provide growth capital.

11 Feb 2011

Life Sciences Discovery Fund announces nearly $600,000 in awards

The Life Sciences Discovery Fund (LSDF) today announced nearly $600,000 in awards to support commercial development of technologies to improve the diagnosis and management of major health conditions.

9 Feb 2011

SwitchGear Genomics, BioCat enter distribution agreement for LightSwitch Luciferase Assay System in Europe

SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company signed an agreement for BioCat GmbH to distribute the innovative LightSwitch Luciferase Assay System™ in Europe.

9 Feb 2011

New England Biolabs expands line of reagents for sample preparation

New England Biolabs has expanded its line of reagents for sample preparation upstream of next generation sequencing to include NEBNext® Small RNA Sample Prep Set 1 for sequencing on the Illumina® platforms, and NEBNext Small RNA Sample Prep Set 3 for sequencing on LIFE's SOLiD™ platform. These new products offer a new and unique protocol, which results in higher yields and lower adaptor-dimer formation, as compared to other protocols.

From New England Biolabs 3 Feb 2011

Automation protocols for TruSeq kits is now available in Sciclone NGS Workstation

Caliper Life Sciences, today announced that it has developed and optimized automation protocols on its Sciclone NGS Workstation for Illumina's TruSeq DNA and TruSeq RNA sample preparation kits.

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.